Robert Lefkowitz (L) and Septerna CEO Jeffrey Finer
Septerna’s $150M infusion will help prove whether it’s got the right pill for hypoparathyroidism
A hefty Series B will bankroll Septerna’s first clinical trial, which will be a key test of whether the company’s pill will be the first …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
